Business context and reporting period
This is Quintiles Transnational Holdings Inc.’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2015, compared with the corresponding 2014 periods. The filing describes two segments: Product Development and Integrated Healthcare Services. The request identifies IQVIA Holdings Inc.; the supplied filing names Quintiles Transnational Holdings Inc. as registrant, so confirm the intended issuer and corporate-history mapping.
Financial performance and position
| Metric | Q3 2015 | Q3 2014 | Nine months 2015 | Nine months 2014 |
|---|---|---|---|---|
| Service revenue | $1,093.5m | $1,061.0m | $3,197.8m | $3,101.8m |
| Total revenue, including reimbursed expenses | $1,424.8m | $1,400.0m | $4,215.9m | $4,048.9m |
| Operating income | $167.0m | $149.1m | $468.6m | $431.5m |
| Net income attributable to Quintiles | $111.3m | $92.7m | $282.6m | $268.0m |
| Diluted EPS | $0.89 | $0.71 | $2.24 | $2.03 |
Service revenue increased 3.1% in both comparison periods as reported. Management attributed constant-currency growth of 8.3% for Q3 and 8.8% for the nine months to business growth, partly offset by adverse foreign-exchange effects of approximately $55.6m and $176.8m, respectively. Service costs were 62.5% of service revenue in Q3 (65.1% prior year) and 63.4% for nine months (64.8%); improved Product Development margins and currency effects contributed. Consolidated operating income rose 12.0% in Q3 and 8.6% for nine months.
For Q3, Product Development revenue was $810.0m and operating margin 22.4%, up from 20.5%; Integrated Healthcare Services revenue was $283.4m and margin 8.5%, up from 6.9%. Nine-month segment margins were 21.9% and 7.1%, respectively. Net income included a $7.8m debt-extinguishment loss in the nine-month period and $6.0m of contingent-consideration remeasurement expense. Interest expense was $76.3m for nine months.
Nine-month operating cash flow was $269.4m, versus $175.8m; investing cash outflow was $39.4m versus $145.9m; financing provided $21.7m versus $144.4m used. Capital spending on property, equipment and software was $56.7m, implying approximate operating cash flow less that spending of $212.7m. Cash and equivalents were $1,081.8m at September 30, 2015, including $411.9m in the United States. Current assets were $2,520.2m and current liabilities $1,524.0m.
Total debt was approximately $2.5bn, with no revolving-facility borrowings; disclosed additional availability was $534.3m. Cash exceeded debt’s current portion, but the company noted that repatriating some foreign cash could have adverse tax consequences. Total shareholders’ deficit was $179.9m.
Material changes versus prior periods
- On July 1, 2015, Quintiles combined its clinical-trial laboratory operations with Quest Diagnostics’ operations to form Q2 Solutions. Quintiles controls and consolidates the venture; Quest holds 40%. The transaction added $263.2m of goodwill and $125.9m of identifiable intangibles; acquired operations were included from the closing date.
- May refinancing replaced the prior term loan with $850m Term Loan A, $600m Term Loan B, and $800m of 4.875% senior notes due 2023. It also established a $500m revolver. The filing reports a $7.8m extinguishment loss and termination-related swap costs.
- The company repurchased 3.86m shares for approximately $250m in May. Share repurchases reduced the share count; weighted-average basic shares for Q3 fell to 122.8m from 127.5m.
- Backlog was $11.748bn, up from $11.244bn at year-end 2014. Net new business declined 23.0% in Q3 to $1.164bn and 4.5% for nine months to $3.832bn. Approximately $8.020bn of backlog was not expected to produce revenue within 12 months.
Outlook, commentary, risks and unusual items
No formal revenue or earnings guidance is stated. Management said available cash, expected operating cash flow and credit-facility access should fund operations, capital expenditures and debt obligations for at least 12 months. Restructuring plans are expected to generate $50m–$60m in annualized savings. The February 2015 plan was approximately $30m; a separate Q2 Solutions-related plan is approximately $14m. The company recorded $23.5m of restructuring costs in the first nine months, with remaining actions expected through 2017.
Management cited stronger execution on Product Development backlog, while warning of elevated billable headcount and compensation costs as projects ramp. Q3 net new business fell in both segments: Product Development faced comparison with a large prior-year functional-resourcing renewal; Integrated Healthcare Services was affected by a large North American commercial-services cancellation and weaker signings in Japan and real-world research. Foreign currency remains a material sensitivity: approximately 32% of nine-month service revenue was denominated in currencies other than the U.S. dollar.
Risks identified include short-notice contract termination, pricing and cost overruns, delayed change-order approvals, uncertainty in backlog conversion, customer or therapeutic concentration, international and currency exposure, regulatory and patient-safety liabilities, acquisition integration, and substantial indebtedness. Debt agreements include restrictive covenants and mandatory excess-cash-flow repayments beginning in 2016; the company reported covenant compliance. Legal matters were described as incidental and not expected to have a material adverse effect, though outcomes remain uncertain. Management concluded disclosure controls were effective and reported no material change in internal control over financial reporting.
Important facts for investors to verify
- Confirm the intended issuer: the filing is for Quintiles Transnational Holdings Inc., not under the IQVIA name shown in the request metadata.
- Assess whether backlog converts to revenue and cash as expected, particularly given the year-over-year decline in net new business and the $8.020bn not expected to convert within 12 months.
- Track Q2 Solutions integration, reported contribution, noncontrolling-interest effects and any changes to acquisition-date fair values.
- Review debt maturities, interest-rate exposure, refinancing terms, covenant headroom and the effect of required cash-flow repayments.
- Monitor cash conversion and receivables: management reported a nine-day increase in DSO during the first nine months of 2015.
- Verify delivery and timing of the projected $50m–$60m annualized restructuring savings against remaining costs and execution risks.